Paying for Cures:

Self-Insured Employers Workshop

Learn innovative financing strategies to make cell and gene therapies accessible
and sustainable.

 
Image

Paying for Cures:

Self-Insured Employers Workshop

Learn innovative financing strategies to make cell and gene therapies accessible
and sustainable.

Durable, potentially curative therapies for genetic disorders and cancer have arrived. Short—even single dose—treatment regimens yield lasting health benefits, but large single payments will challenge the current reimbursement system.

In this virtual workshop the FoCUS Project will help you explore the impact of cell and gene therapies on your health benefit plans, survey the risks, and learn about solutions.

June 17, 2021 

11:00am – 3:00pm Eastern via Web conference

Registration is free

This intensive 1-day virtual workshop will help you: 

  • Understand how these therapies are different
  • Explore new solutions and support resources
  • Discover actionable and affordable steps to ensure sustainable coverage and access

Ideal for:

  • Self-insured employer health benefits and finance professionals
  • Other advisors and partners such as self-insured employer brokers, consultants and stop-loss carriers
Image Image Image

Workshop archive

Self-Insured Employers Workshop Presentation

You can now download the archive of decks presented in the workshop.

Get the presentation archive

New White Paper: Emerging Market Solutions

Our research and analysis based on a survey of solution providers shows what's available, what's missing, and what might fit your needs.

Get the white paper

Precision Financing Strategies Toolkit

Learn more about the challenges, potential solutions, and with interactive calculators, how to assess your risk and plan for the future,

Visit the Toolkit

Agenda

Welcome and introductions

Framing the issues
Introduction to FoCUS, and to the unique challenges/risks cell & gene therapies present to self-insured employers.

Jane Barlow, Senior Advisor, NEWDIGS FoCUS Project

Framing the solutions
Precision financing solutions, including the free Paying for Cures online toolkit, to address risks of currently approved treatments and near-term pipeline of expected products.

Mark Trusheim, Strategic Director, NEWDIGS; FoCUS Project Lead; Visiting Scientist at MIT Sloan School of Management

Implications of cell & gene therapies on stop-loss coverage

Mehb KhojaChief Actuary at BCS Financial and President of Medical Risk Managers

New commercial solutions

Michelle Harika, Chief Clinical Officer for Equity Healthcare

Panel & Discussion

Actions self-insured employers can take today

Mark TrusheimMIT NEWDIGS and moderator
Michelle Harika, Chief Clinical Officer for Equity Healthcare
Mehb Khoja, Chief Actuary at BCS Financial and President of Medical Risk Managers
Cynthia Pigg, Senior Vice President, AON
Luke Prettol, Lead Benefits Strategy Consultant at AT&T

Thanks and conclusion

Jane Barlow, Senior Advisor, NEWDIGS FoCUS Project

Agenda

Welcome and introductions

Mark Trusheim, Strategic Director, NEWDIGS; FoCUS Project Lead; Visiting Scientist at MIT Sloan School of Management
Gigi Hirsch, Executive Director, MIT Center for Biomedical Innovation (CBI); Director, NEWDIGS Initiative at MIT

Framing the Issues
Definition of Cell and Gene Therapies and their unique challenges/risks for self-insured employers including toolkit.

Mark Hansan, President and CEO, CareMetx

Drug development pipeline
Currently approved treatments and near-term pipeline of expected products

Colin Young, Director, Drug Development Pipeline Research, NEWDIGS FoCUS Project

Implications for stop-loss coverage

Jane Barlow, Senior Advisor, NEWDIGS FoCUS Project and Moderator

New commercial solutions

Jane Barlow, Senior Advisor, NEWDIGS FoCUS Project and Moderator

PANEL & DISCUSSION

Actions self-insured employers can take today

Jane Barlow, Senior Advisor, NEWDIGS FoCUS Project and Moderator

Recap and conclusion

Mark Trusheim, Strategic Director, NEWDIGS; FoCUS Project Lead; Visiting Scientist at MIT Sloan School of Management

Speakers

Image

Jane F. Barlow, MD, MBA, MPH
CEO, Jane Barlow & Associates; 
EVP and Chief Clinical Officer, Real Endpoints; 
Senior Advisor, MIT Center for Biomedical Innovation, NEWDIGS

Image

Michelle Harika, PharmD
Chief Clinical Officer for Equity Healthcare

Mehb Khoja portrait

Mehb Khoja
Chief Actuary at BCS Financial and President of Medical Risk Managers

Image

Cynthia J. Pigg, BSMT, BSPharm, MHA, FAMCP
Senior Vice President, Commercial Market Leader, Pharmacy, AON

Luke Prettol

Luke Prettol, CEBS HCS PHR
Lead Benefits Strategy Consultant at AT&T

Image

Mark Trusheim, MS
Strategic Director, NEWDIGS;
Visiting Scientist, Sloan School of Management,
Massachusetts Institute of Technology

Agenda

Welcome and introductions

Mark Trusheim, Strategic Director, NEWDIGS; FoCUS Project Lead; Visiting Scientist at MIT Sloan School of Management
Gigi Hirsch, Executive Director, MIT Center for Biomedical Innovation (CBI); Director, NEWDIGS Initiative at MIT

Framing the Issues
Definition of Cell and Gene Therapies and their unique challenges/risks for self-insured employers including toolkit.

Mark Hansan, President and CEO, CareMetx

Drug development pipeline
Currently approved treatments and near-term pipeline of expected products

Colin Young, Director, Drug Development Pipeline Research, NEWDIGS FoCUS Project

Implications for stop-loss coverage

Jane Barlow, Senior Advisor, NEWDIGS FoCUS Project and Moderator

New commercial solutions

Jane Barlow, Senior Advisor, NEWDIGS FoCUS Project and Moderator

PANEL & DISCUSSION

Actions self-insured employers can take today

Jane Barlow, Senior Advisor, NEWDIGS FoCUS Project and Moderator

Recap and conclusion

Mark Trusheim, Strategic Director, NEWDIGS; FoCUS Project Lead; Visiting Scientist at MIT Sloan School of Management

Registration

June 17, 11:00am – 3:00pm
Zoom Web conference
Registration is free